Remicade® (infliximab): 20 years of contributions to science and medicine

Código QR

Remicade® (infliximab): 20 years of contributions to science and medicine

Richard Melsheimer,1 Anja Geldhof,1 Isabel Apaolaza,1 Thomas Schaible21Medical Affairs, Janssen Biologics BV, Leiden, the Netherlands; 2Medical Affairs, Janssen Pharmaceuticals, Horsham, PA, USAAbstract: On August 24, 1998, Remicade® (infliximab), the first tumor necrosis factor-α...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Melsheimer R, Geldhof A, Apaolaza I, Schaible T
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	Remicade (infliximab) monoclonal antibody immune-mediated inflammatory disease TNF inhibition Crohn’s disease rheumatoid arthritis Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/39743cf03df04a5983b7e4012f9b7747
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Rol de infliximab en enfermedad inflamatoria intestinal: Experiencia local
por: Simian,Daniela, et al.
Publicado: (2013)

Infliximab en el tratamiento de la enfermedad de Crohn: Estudio preliminar
por: Gellona V,José, et al.
Publicado: (2006)

Eficacia y seguimiento en el largo plazo de pacientes con psoriasis vulgar moderada a severa en tratamiento con infliximab (Remicade®)
por: Valdés A,María del Pilar, et al.
Publicado: (2006)

A descriptive analysis of real-world treatment patterns of innovator (Remicade®) and biosimilar infliximab in an infliximab-naïve Turkish population
por: Yazici Y, et al.
Publicado: (2018)

DYNAMICS OF CYTOKINE PROFILE IN PATIENTS WITH RHEUMATOID ARTHRITIS AS INFLUENCED BY INFLIXIMAB (REMIKEID) ADMINISTRATION
por: E. S. Zhugrova, et al.
Publicado: (2014)

Efficacy of ustekinumab against infliximab-induced psoriasis and arthritis associated with Crohn’s disease
por: Matsumoto S, et al.
Publicado: (2018)

Utilidad de la monitorización terapéutica de infliximab en el manejo de la enfermedad inflamatoria intestinal
por: Quera,Rodrigo, et al.
Publicado: (2018)

Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab
por: Fitzgerald T, et al.
Publicado: (2021)

Evaluación del tratamiento con infliximab en enfermos con artritis inflamatoria refractaria a drogas habituales
por: Labarca S,Cristián, et al.
Publicado: (2003)

Infliximab Efficacy May Be Linked to Full TNF-α Blockade in Peripheral Compartment—A Double Central-Peripheral Target-Mediated Drug Disposition (TMDD) Model
por: David Ternant, et al.
Publicado: (2021)

Infliximab dose adjustment can improve the clinical and radiographic outcomes of rheumatoid arthritis patients: REVIVE study results
por: Nozaki Y, et al.
Publicado: (2018)

Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives
por: Rawla P, et al.
Publicado: (2018)

Efficacy of adalimumab as second-line therapy in a pediatric cohort of Crohn’s disease patients who failed infliximab therapy: the Italian Society of Pediatric Gastroenterology, Hepatology, and Nutrition experience
por: Alvisi P, et al.
Publicado: (2019)

Gut Microbiota Offers Universal Biomarkers across Ethnicity in Inflammatory Bowel Disease Diagnosis and Infliximab Response Prediction
por: Youlian Zhou, et al.
Publicado: (2018)

Tumor inflamatorio miofibroblástico peritoneal. Respuesta favorable asociada a infliximab: Caso clínico
por: Grünholz,Daniela, et al.
Publicado: (2015)

TUMOR NECROSIS FACTOR-α MEMBRANE-BOUND AND SOLUBLE RECEPTORS IN NORM AND IN RHEUMATOID ARTHRITIS
por: A. A. Alshevskaya, et al.
Publicado: (2012)

A Practical Guide to Therapeutic Drug Monitoring of Biologic Medications for Inflammatory Bowel Disease
por: Byron P. Vaughn
Publicado: (2021)

Infliximab in Combination with Low-Dose Acitretin in Generalized Pustular Psoriasis: A Report of Two Cases and Review of the Literature
por: Kołt-Kamińska M, et al.
Publicado: (2021)

Therapeutic effects of lornoxicam-loaded nanomicellar formula in experimental models of rheumatoid arthritis
por: Helmy HS, et al.
Publicado: (2017)

Clinical Outcomes in Iraqi Patients with Rheumatoid Arthritis Following Earlier or Later Treatment with Etanercept
por: Al-Ani N, et al.
Publicado: (2021)

ROLE OF TUMOR NECROSIS FACTOR ALPHA IN IMMUNE PATHOGENESIS OF DIFFERENT DISEASES AND ITS SIGNIFICANCE FOR EVOLVING ANTICYTOKINE THERAPY WITH MONOCLONAL ANTIBODIES
por: E. V. Voronina, et al.
Publicado: (2018)

AUTOANTIBODIES TO CIRTULLINATED ANTIGENS FOR DIAGNOSIS AND PREDICTION OF CLINICAL COURSE IN EARLY RHEUMATOID ARTHRITIS
por: I. B. Belyaeva, et al.
Publicado: (2014)

PROMOTER POLYMORPHISM -857С>T OF TNFα GENE AND EFFICACY OF ANTICYTOKINE THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS
por: A. N. Silkov, et al.
Publicado: (2014)

A practical guide about biosimilar data for health care providers treating inflammatory diseases
por: Markenson J, et al.
Publicado: (2017)

Enfermedades inflamatorias intestinales: Experiencia de dos centros chilenos
por: Figueroa C,Carolina, et al.
Publicado: (2005)

Diagnostic value of anti-GP2 antibodies determined in serum and coprofiltrates in children with inflammatory bowel disease
por: A. P. Toptygina, et al.
Publicado: (2020)

ROLE OF IL-6 IN EXPERIMENTAL ARTHRITIS CAUSED BY TRANSFER OF ARTHRITOGENIC ANTIBODIES
por: M. S. Drutskaya, et al.
Publicado: (2016)

Role of TNFα and IL-10 in rheumatoid arthritis and association with some HLA II DR and DQ alleles
por: N. Alsalih, et al.
Publicado: (2020)

Artritis reumatoidea en población mapuche.: Una experiencia de 16 años en la IX región de Chile
por: Kaliski K,Sonia, et al.
Publicado: (2001)

Valor pronóstico del índice de Sharp en la respuesta clínica y de laboratorio a un pulso intravenoso de metilprednisolona en pacientes con artritis reumatoídea
por: Cuchacovich T,Miguel, et al.
Publicado: (2000)

Programmed cell death 5 transgenic mice attenuates adjuvant induced arthritis by 2 modifying the T lymphocytes balance
por: Yuan,Feng, et al.
Publicado: (2017)

Rheumatoid Arthritis Saudi Database (RASD): Disease Characteristics and Remission Rates in a Tertiary Care Center
por: Almoallim H, et al.
Publicado: (2020)

CLINICAL AND IMMUNOLOGICAL PARAMETERS IN EARLY RHEUMATOID ARTHRITIS
por: V. V. Sokolova, et al.
Publicado: (2014)

Hyperuricemia Among Egyptian Rheumatoid Arthritis Patients. Is It an Association or an Inflammatory Marker? A Cross-Sectional Observational Study
por: Nada D, et al.
Publicado: (2021)

Effects of dexamethasone, celecoxib, and methotrexate on the histology and metabolism of bone tissue in healthy Sprague Dawley rats
por: Liu YZ, et al.
Publicado: (2015)

Polyphenols Targeting MAPK Mediated Oxidative Stress and Inflammation in Rheumatoid Arthritis
por: Tapan Behl, et al.
Publicado: (2021)

Biomarcadores en enfermedad inflamatoria intestinal: ¿sabe cómo utilizarlos?
por: Pérez de Arce,Edith, et al.
Publicado: (2020)

Experiencia local con natalizumab en pacientes con enfermedad de Crohn refractaria a anti-TNF: Casos clínicos
por: Fluxá,Daniela, et al.
Publicado: (2017)

Enfermedad inflamatoria intestinal a partir de una experiencia local
por: Simian,Daniela, et al.
Publicado: (2014)

An overview of the biological disease modifying drugs available for arthritic conditions in South Africa
por: Leonie Harmse, et al.
Publicado: (2016)